share_log

信達生物：截至2024年2月29日止月份之股份發行人的證券變動月報表

INNOVENT BIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024

香港交易所 ·  Mar 6 09:40
Summary by Moomoo AI
信達生物製藥於2024年2月29日向香港交易及結算所有限公司提交了最新的證券變動月報表。報告顯示，公司的法定/註冊股本及已發行股份在2月份均無變動，普通股股份數目維持在5,000,000,000股，面值為0.00001美元，總額為50,000美元。同時，已發行股份結存數目為1,622,582,897股。股份期權方面，首次公開發售前股份獎勵計劃及首次公開發售後僱員持股計劃的股份期權數目本月無變動，分別為20,443,211股和53,436,699股。此外，信達生物製藥2018受限制股份計劃已終止，而2020受限制股份計劃則無新股份發行。報告中未提及有關香港預託證券的資料。報告由聯席公司秘書王豔菊於2024年3月6日呈交。
信達生物製藥於2024年2月29日向香港交易及結算所有限公司提交了最新的證券變動月報表。報告顯示，公司的法定/註冊股本及已發行股份在2月份均無變動，普通股股份數目維持在5,000,000,000股，面值為0.00001美元，總額為50,000美元。同時，已發行股份結存數目為1,622,582,897股。股份期權方面，首次公開發售前股份獎勵計劃及首次公開發售後僱員持股計劃的股份期權數目本月無變動，分別為20,443,211股和53,436,699股。此外，信達生物製藥2018受限制股份計劃已終止，而2020受限制股份計劃則無新股份發行。報告中未提及有關香港預託證券的資料。報告由聯席公司秘書王豔菊於2024年3月6日呈交。
SINDA BIOPHARMACEUTICALS FILED ITS LATEST MONTHLY SECURITIES CHANGE REPORT WITH HONG KONG TRADING AND SETTLEMENT LIMITED ON 29 FEBRUARY 2024. The report shows that the company's regulary/registered share capital and issued shares were unchanged in February, and the number of ordinary shares remained at 5,000,000,000 shares with a face value of $0.00001 for a total of $50,000. At the same time, the number of issued share deposits is 1,622,582,897 shares. In terms of stock options, the number of share options under the Initial Public Offering Pre-IPO Share Award Scheme and the Post IPO Employee Stock Holding Plan remained unchanged for the month at 20,443,211 shares and 53,436,699 shares, respectively. IN ADDITION, SINDA BIOPHARMACEUTICS' 2018 RESTRICTED SHARE PLAN HAS BEEN TERMINATED AND NO NEW SHARES HAVE BEEN ISSUED IN THE 2020 RESTRICTED SHARE PLAN. No information on Hong Kong pre-trust securities is mentioned in the report. The report was presented by the Joint Secretary of the Joint Undertaking, Mr. Wang, on 6 March 2024.
SINDA BIOPHARMACEUTICALS FILED ITS LATEST MONTHLY SECURITIES CHANGE REPORT WITH HONG KONG TRADING AND SETTLEMENT LIMITED ON 29 FEBRUARY 2024. The report shows that the company's regulary/registered share capital and issued shares were unchanged in February, and the number of ordinary shares remained at 5,000,000,000 shares with a face value of $0.00001 for a total of $50,000. At the same time, the number of issued share deposits is 1,622,582,897 shares. In terms of stock options, the number of share options under the Initial Public Offering Pre-IPO Share Award Scheme and the Post IPO Employee Stock Holding Plan remained unchanged for the month at 20,443,211 shares and 53,436,699 shares, respectively. IN ADDITION, SINDA BIOPHARMACEUTICS' 2018 RESTRICTED SHARE PLAN HAS BEEN TERMINATED AND NO NEW SHARES HAVE BEEN ISSUED IN THE 2020 RESTRICTED SHARE PLAN. No information on Hong Kong pre-trust securities is mentioned in the report. The report was presented by the Joint Secretary of the Joint Undertaking, Mr. Wang, on 6 March 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more